Instant NanoBiosensors focuses mainly on the development of the Light-Sensing Protein & Nucleic Acid Biomarker Portable Platform that utilizes the technology combing FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) to revolutionize traditional immunoassays and analysis for a more efficient healthcare ecosystem. We believe that the integration of nanotechnology into biosensors will benefit the world by moving bioanalysis from the laboratory to any point of use. The vision of our company is to be the pioneer and leader in portable biosensors platforms for protein and nucleic acid biomarkers in the next five years.
In May 2019, we launched Light Sensing Biomarker Analyzer in the life science research market, enabling molecule measurement of proteins, nucleic acids and cells. For this, we won the first overseas order from Brigham and Women's Hospital (BWH), a teaching hospital of Harvard Medical School. We have been extremely active in establishing collaborations with over a dozen medical and academic institutes both in Taiwan and overseas. Apart from the clinical collaboration on kidney disease with BWH, it has also recently completed a clinical study in collaboration with the Department of Neurology at National Taiwan University.
In 2020, we were one of the innovative young companies for worldwide strategic collaboration selected by Merck KGaA because of our unique fiber optic microfluidics nano-chip technology. The technology can shorten the time consumed in detecting biomarker in laboratories from three hours to just several minutes, and enhance the detection sensitivity (fg/ml) which allows our product to gather data comparable to top diagnostic laboratories. We hope through our products we can realize our dream of “immediate care” to make health care quicker, cheaper, and more comfortable without sacrificing quality.
